Structure Therapeutics (GPCR) Shares Outstanding (Diluted Average) (2023 - 2026)

Structure Therapeutics' Shares Outstanding (Diluted Average) history runs 4 years deep, the most recent figure standing at $217.3 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Diluted Average) rose 26.31% year-over-year to $217.3 million; the TTM figure through Mar 2026 stood at $217.3 million (up 26.31% YoY), while the FY2025 annual figure was $177.6 million, up 12.46% from the prior year.
• Shares Outstanding (Diluted Average) was $217.3 million for Q1 2026 at Structure Therapeutics, up from $177.6 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $217.3 million in Q1 2026 to a low of $110.2 million in Q4 2023.
• Historically, Shares Outstanding (Diluted Average) has averaged $163.8 million across 4 years, with a median of $171.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Diluted Average) soared 43.31% in 2024, then advanced 2.24% in 2025.
• A 4-year view of Shares Outstanding (Diluted Average) shows it stood at $110.2 million in 2023, then surged by 43.31% to $157.9 million in 2024, then rose by 12.46% to $177.6 million in 2025, then increased by 22.37% to $217.3 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $217.3 million (Q1 2026), $177.6 million (Q4 2025), and $175.5 million (Q3 2025), per Business Quant data.